SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 13, 2017 — Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies 2017 London Healthcare Conference on Wednesday, November 15, 2017 at 12:40 p.m. GMT / 7:40 a.m. ET.
A live webcast of the presentation will be available online from the investor relations page of the company's corporate website at http://ir.immunedesign.com/events.cfm. After the live webcast, an archive of the presentation will be available on the company website for 30 days.About Immune DesignImmune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the two leading product candidates focused in cancer immunotherapy, are the first products from Immune Design's two separate discovery platforms targeting dendritic cells in vivo, ZVex® and GLAAS®. Both ZVex and GLAAS also have potential applications in infectious disease and allergy as demonstrated by ongoing pharmaceutical collaborations. Immune Design has offices in Seattle and South San Francisco.Media Contact
[email protected] 206-769-9219Investor Contact
Latest posts by Sarah Thompson (see all)
- MWC 2018: Faststream Technologies Lightening the way to Ambient Intelligence for Move Towards Intelligent Systems - February 23, 2018
- NuLife4D and their Life4D Token Launch their ICO, Soon Printing a Human Heart On Demand Will No Longer be Sci-Fi - February 23, 2018
- â€œThe Portrait Mastersâ€� Conference + Expo 2018 Sells Out in One Week - February 23, 2018